Balanopostitis severa secundaria al tratamiento con imiquimod tópico / Severe balanoposthitis secondary to treatment with topical imiquimod

No disponible

Erosión externa, complicación del esfínter urinario artificial / External erosion. Artificial urinary sphincter complication

No disponible

Quiste intrabdominal y retención crónica de orina / Abdominal cyst and chronic urinary retention

No disponible

Quiste gigante de próstata / Giant cyst of the prostate

No disponible

Results of the treatment of anterior pelvic organ prolapse using the Perigee® system.

OBJECTIVES: To study the efficacy and safety of the Perigee® System for the treatment of anterior vaginal prolapse in our experience with a medium term follow-up. METHODS: Prospective analysis on 48 consecutive patients with stage II-IV cystocele diagnosed from June 2006 until June 2009 using the Pelvic Organ Prolapse Quantitation classification without other associated prolapses. All diagnoses were done by a single urological specialist and follow-up is between 3 to 6 years. The questionnaire Patient Global Impression of Improvement was carried out before surgery, at the first follow up checking at one month, and at 6 and 12 months. The variables evaluated were age, presence of obesity, parity, prior hysterectomy, ASA class and stage of prolapse. RESULTS: The result, evaluating the questionnaire Patient Global Impression of Improvement, was cured or improved in 40 (83.3%) patients and 87.5% according to the Pelvic Organ Prolapse Quantitation, with a recurrence rate of 6.25%. Intraoperative complications were observed in 12.5% of the patients, postoperative in 4.2% and 41.5% after hospital discharge, pain being the most common complication (16.6%). The key variables for procedural failure were age 65 years >, obesity, parity ≥ 2, prolapse stage ≥ III and prior hysterectomy (p <0.05). CONCLUSIONS: In our series the Perigee® System allows anatomic repair with less morbidity, hospital stay and recovery time.

Resultados a medio plazo del tratamiento del prolapso anterior de órganos pélvicos mediante el sistema Perigee® / Results of teh tratment of anterior pelvic organ prolapse using the Perigee® system

OBJETIVO: Estudiar la eficacia y seguridad según nuestra experiencia del sistema Perigee® para el tratamiento del prolapso vaginal anterior. MÉTODOS: Análisis prospectivo en 48 pacientes consecutivas diagnosticadas mediante la clasificación para la Pelvic Organ Prolapse Quantification (Cuantificación del Prolapso de órganos Pélvicos) (POP-Q) de cistocele estadios II a IV, sin otros prolapsos asociados, desde Junio de 2006 hasta Junio de 2009, realizados por un único urólogo especializado, con un seguimiento de 3 a 6 años. Se ha realizado el cuestionario Patient Global Impression of Improvement (Impresión Global de Mejora del Paciente) (PGI-I) antes de la cirugía, en el primer control al mes, a los 6 y 12 meses. Se evaluaron las variables edad, presencia de obesidad, número de partos, histerectomía previa, clase ASA y estadio de prolapso. RESULTADOS: El resultado, evaluando el cuestionario Patient Global Impression of Improvement, fue de curación o mejoría en 40 (83,3%) pacientes y según la Pelvic Organ Prolapse Quantitation del 87,5%, con una tasa de recidiva del 6,25%. Se observaron complicaciones intraoperatorias en el 12,5% de las pacientes, postoperatorias en el 4,2%, y postalta en 41,5%, siendo el dolor la complicación más frecuente (16,6%). Las variables determinantes del fracaso del procedimiento, estadísticamente significativas (p <0,05), fueron la edad >65 años, obesidad, número de partos ≥ 2, estadio del prolapso ≥ III e histerectomía previa. CONCLUSIONES: En nuestra serie el sistema Perigee® permite la reparación anatómica con menor morbilidad, estancia hospitalaria y tiempo de recuperación

OBJECTIVES: To study the efficacy and safety of the Perigee® System for the treatment of anterior vaginal prolapse in our experience with a medium term follow-up. METHODS: Prospective analysis on 48 consecutive patients with stage II-IV cystocele diagnosed from June 2006 until June 2009 using the Pelvic Organ Prolapse Quantitation classification without other associated prolapses. All diagnoses were done by a single urological specialist and follow-up is between 3 to 6 years. The questionnaire Patient Global Impression of Improvement was carried out before surgery, at the first follow up checking at one month, and at 6 and 12 months. The variables evaluated were age, presence of obesity, parity, prior hysterectomy, ASA class and stage of prolapse. RESULTS: The result, evaluating the questionnaire Patient Global Impression of Improvement, was cured or improved in 40 (83.3%) patients and 87.5% according to the Pelvic Organ Prolapse Quantitation, with a recurrence rate of 6.25%. Intraoperative complications were observed in 12.5% of the patients, postoperative in 4.2% and 41.5% after hospital discharge, pain being the most common complication (16.6%). The key variables for procedural failure were age 65 years >, obesity, parity ≥ 2, prolapse stage ≥ III and prior hysterectomy (p <0.05). CONCLUSIONS: In our series the Perigee® System allows anatomic repair with less morbidity, hospital stay and recovery time

Cutaneous manifestation of renal hematoma after ESWL.

A 73 year-old patient with history of arterial hypertension and regular treatment with antiplatelet agents who presented with an hypotensive episode after extracorporeal shock-wave lithotripsy (ESWL) was diagnosed of right renal hematoma.

Manifestación cutánea de hematoma renal post LEOCH / Cutaneous manifestation of renal hematoma after ESWL

No disponible